FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns area of molecular biology and biochemistry, and can be used in medicine. There is offered mutein conjugate of the blood coagulation factor VIII (FVIII) wherein a residue not being cysteine in position 41, 129, 377, 388, 468, 491, 556, 1804, 1808, 1810, 1812, 1813, 1815 and/or 2118 is substituted by a cysteine residue with polyethylene glycol (PEG) where a PEG molecule is bound with a polypeptide in a mutant cysteine residue.
EFFECT: improved pharmacokinetic properties of the FVIII as an ingredient of the conjugate under the invention with preserved a procoagulant factor activity allows presenting new FVIII PEG-muteins for producing of a pharmaceutical compositions for treating hemophilia.
12 cl, 38 dwg, 8 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| COVALENT MODIFICATION OF POLYPEPTIDES WITH POLYETHYLENE GLYCOLS | 1992 |
|
RU2148586C1 |
| URATE OXIDASE CONJUGATES, PHARMACEUTICAL COMPOSITION FOR REDUCTION IN URIC ACID LEVELS AND METHOD FOR PREPARING CONJUGATES STATED ABOVE | 2008 |
|
RU2443426C2 |
| RECOMBINANT PLASMID DNA pAP227 CODING POLYPEPTIDE OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, LINE OF CELLS Cricetulus griseus CHO, 2H5-PRODUCER OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, AND METHOD FOR OBTAINING POLYPEPTIDE HAVING ACTIVITY OF RECOMBINANT FACTOR VIII | 2012 |
|
RU2500818C1 |
| CONJUGATES OF BLOOD COAGULATION PROTEINS | 2010 |
|
RU2595442C2 |
| BLOOD COAGULATION PROTEIN CONJUGATES | 2010 |
|
RU2744370C2 |
| PREPARATIONS CONTAINING VON WILLEBRAND FACTOR (vWF) AND METHODS, KITS AND APPLICATIONS RELATED TO THEM | 2010 |
|
RU2579977C2 |
| CHEMERIC IMPROVED RECOMBINANT FACTOR VIII | 2015 |
|
RU2647769C2 |
| Fc-FRAGMENT IgG4 CONTAINING MODIFIED HINGE REGION | 2014 |
|
RU2696973C2 |
| PEG-CONTAINING CONJUGATES OF HGF-NK4 | 2002 |
|
RU2293574C2 |
